Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Shubha Bhat, PharmD Fortunately, there are a lot of studies that have evaluated biosimilars in inflammatory bowel disease (IBD), and those all confirmed that biosimilars are safe, effective, and do not result in worsening patient outcomes. But are we using biosimilars enough in the treatment of IBD? Dive in with Dr. Mary Katherine Cheeley as she speaks with Dr. Shubha Bhat, Clinical Pharmacist in the Digestive Disease...

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Chey, MD Roughly 1 in 10 Americans suffer with some degree of constipation, and many of those patients suffer with ongoing chronic issues around constipation. So for the first time, the American Gastroenterological Association and the American College of Gastroenterology have released joint recommendations for the management of chronic idiopathic constipation (CIC). To dive into these guidelines, Dr. Peter Buch is joined by...

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Marianna Arvanitakis, MD, PhD Patients with non-celiac gluten sensitivity can experience the same symptoms of those with celiac disease and IBS, complicating the diagnostic process. Find out how you can accurately identify and distinguish non-celiac gluten sensitivity from other digestive disorders with Dr. Peter Buch and Dr. Marianna Arvanitakis, Associate Clinical Professor in the Department of Gastroenterology,...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Zobair M Younossi MD, MPH, FACP, FACG, AGAF, FAASLD Guest: Alan H.B. Wu, PhD Liver disease patients are at an increased risk of major adverse cardiovascular events (MACE), which is why the doctor in today’s episode believes the multidisciplinary team plays an essential role in managing these patients. Tune in with Dr. Charles Turck as he speaks with Dr. Zobair Younossi, Chair of the Global NASH Council and Professor of Medicine...

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: John Pandolfino, MD, MSCI There are a wide range of therapeutic options when it comes to personalizing your patient’s treatment approach, such as simple lifestyle modifications all the way to a surgical procedure. To learn more, tune in with Dr. Peter Buch as he speaks with Dr. John Pandolfino, Hans Popper Professor and Chief of Gastroenterology and Hepatology in the Department of Medicine at Northwestern Medicine Feinberg School of...

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Douglas Drossman, MD We all face angry and disruptive patients from time to time, making it essential to know how to properly de-escalate and handle the situation. That’s why Dr. Peter Buch speaks with Dr. Douglas Drossman, co-author of an article that was published in the American Journal of Gastroenterology titled “De-escalate, Don’t Escalate: Essential Steps to Effectively Recognize and Manage the Patient Who Is Angry and...

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Siddharth Singh, MD How can we use biomarkers to treat patients with ulcerative colitis? That’s the exact question the latest guideline from the American Gastroenterological Association (AGA) sought to address. Learn about this guideline and other best practices with Dr. Peter Buch and Dr. Siddharth Singh, Assistant Professor of Medicine at the University of California-San Diego and co-author of an article published in...

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Alan Bonder, MD According to the United Network for Organ Sharing (UNOS), more than 95 percent of patients are alive and doing well after a liver transplant. So what else can we learn from UNOS? Join Dr. Peter Buch as he speaks with Dr. Alan Bonder, Assistant Professor of Medicine at Harvard Medical School.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Suijit Janardhan, MD, PhD Diabetic patients have a significant risk for developing more advanced liver disease, and the disease that they’re particularly at risk for is steatotic liver disease. Dive into this episode to learn more with Dr. Charles Turck and Dr. Sujit Janardhan, Assistant Professor in the Department of Internal Medicine, Division of Digestive Diseases and Nutrition, and the Department of Transplant Surgery at Rush...

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Kunal Jajoo, MD The American Gastroenterological Association (AGA) recently published updated clinical guidelines for the use of endoscopic ultrasound (EUS). Are there caveats involved with these recommendations? Join Dr. Peter Buch as he speaks with Dr. Kunal Jajoo, Assistant Professor of Medicine at Harvard Medical School, about the best utilization of EUS in clinical practice.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Herbert L. Bonkovsky, MD If an elevation of delta aminolevulinic or porphobilinogen occurs in the urine more than three times what is normal, that is presumptive acute hepatic porphyria (AHP. Join the conversation as Dr. Peter Buch speaks with Dr. Herbert Bonkovsky, Professor of Medicine and Molecular Medicine and Translational Science at Wake Forest University, about his article published in Gastroenterology.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Sidney Barritt, MD Even though nonalcoholic fatty liver disease is the most common form of chronic liver disease in the United States, there are unfortunately no FDA-approved medications for this condition. That’s why Dr. Peter Buch speaks with Dr. Sidney Barritt about top treatment strategies for nonalcoholic fatty liver disease in part one of this two-episode series. Dr. Barritt is an Associate Professor of Medicine and the...

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Sidney Barritt, MD Even though nonalcoholic fatty liver disease is the most common form of chronic liver disease in the United States, there are unfortunately no FDA-approved medications for this condition. That’s why Dr. Peter Buch speaks with Dr. Sidney Barritt about even more treatment strategies for nonalcoholic fatty liver disease in the second and final part of this two-episode series. Dr. Barritt is an Associate Professor of...

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Marianna Arvanitakis, MD, PhD Consuming ultra-processed foods can pose many risks to your health that go beyond the GI system. Explore the risks associated with ultra-processed foods with Dr. Peter Buch and Dr. Marianna Arvanitakis, Associate Clinical Professor in the Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology from the HUB Erasme Hospital in Brussels, Belgium.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Claire Jansson-Knodell, MD When a person has a low IgA level, the tissue transglutaminase immunoglobulin A antibody is no longer a useful screening test for celiac disease. So how should we be assessing patients with an IgA deficiency? To discuss these new recommendations, Dr. Peter Buch is joined by Dr. Claire Jansson-Knodell, Gastroenterologist at the Cleveland Clinic’s Digestive Disease Institute.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD Metoclopramide is the only FDA-approved medication for the treatment of gastroparesis; however, it comes with a black box warning. To discuss the challenges in diagnosing and treating gastroparesis, Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine, Pharmacology, and Physiology at the Mayo Clinic in Rochester, Minnesota.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Alan Bonder, MD According to this clinician, the most important thing for primary biliary cholangitis (PBC) patients is the diagnosis, and anyone with abnormal liver tests should be sent an antimitochondrial antibody (AMA). Dive into this interview with host Dr. Peter Buch and Dr. Alan Bonder, Assistant Professor of Medicine and the Medical Director of Liver Transplantation at Beth Israel Medical Center in Boston.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE Assessing eosinophilic esophagitis (EOE) patients’ sensitivity to specific foods is key to creating a personalized diet to help treat this disease. So what role does the six-food elimination diet have in EOE patients? Dive in with Dr. Peter Buch as he speaks with Dr. Brooks Cash, Chief of the Division of Gastroenterology, Hepatology, and Nutrition at the University of Texas Health Sciences...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Paul Kwo, MD Hepatitis B and C are both highly prevalent infections around the world. However, many individuals are not aware of their infection, which can lead to progressive liver damage and other health consequences. This is just one of the many unmet needs in the hepatitis care continuum, and joining Dr. Charles Turck to help uncover those unmet needs and discuss how the latest management strategies can help address them is Dr....

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Scott D. Isaacs, MD FACP, FACE Since type 2 diabetes is the number one risk factor for the progression to advanced liver fibrosis, monitoring diabetic patients is absolutely critical, especially considering the fact that the symptoms of disease progression can be nonexistent or very vague. Here with Dr. Mary Katherine Cheeley to break down the latest guidelines and strategies for monitoring liver health in patients...

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Kunal Jajoo, MD Clinicians should be assessing their patients immediately and trying to understand how quickly they need to provide endoscopy and endoscopic therapy. So in patients with a high risk for thromboembolism, how soon after GI bleeding may anticoagulation be considered? Take a deep dive with Dr. Peter Buch as he speaks with Dr. Kunal Jajoo, Assistant Professor of Medicine at the Brigham and Women’s Hospital of Harvard...

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Alan Bonder, MD Patients with underlying autoimmune diseases could be at a higher risk of developing autoimmune hepatitis (AIH). So what challenges might occur when diagnosing patients with AIH? Learn more with Dr. Peter Buch as he discusses this with Dr. Alan Bonder, Director of Liver Transplantation at Beth Israel Deaconess Hospital and an Assistant Professor of Medicine at Harvard Medical School.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Robert Wong, MD There may be benefit in testing all hepatitis B patients for hepatitis D, such as reducing the risk of disease progression and liver disease complications. So when should we be concerned about potential hepatitis D infection in our patients? Join Dr. Peter Buch as he discusses this with Dr. Robert Wong, Clinical Associate Professor at Stanford University.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Neil Sengupta, MD Lower GI bleeding is one of the most common reasons that patients are hospitalized due to a digestive disorder in the U.S.; however, there is little data available to help clinicians manage this condition in their patients. So how can we provide better care for these patients? Tune in with Dr. Peter Buch as he speaks with Dr. Neil Sengupta, Associate Professor of Medicine at the University of Chicago.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Eamonn Quigley, MD A new treatment option may help relieve chronic constipation in patients who might not respond well to traditional therapies. To learn more about a novel FDA-approved vibrating capsule, join Dr. Peter Buch as he speaks with Dr. Eamonn Quigley, the David M. Underwood Chair of Medicine in Digestive Disorders and a Professor of Medicine at Houston Methodist.